The effect of indomethacin on tumor regression in DMBA-induced epithelial neoplasia of hamster cheek pouch mucosa.
Tumors were allowed to develop in the cheek pouches in two groups of hamsters following topical application three times per week of a 0.5% solution of 7, 12-dimethylbenz(alpha)anthracene (DMBA) in liquid paraffin administered for 10 weeks. Two control groups received no DMBA treatment. After carcinogen application, the animals in one DMBA-treated group and those in one of the control groups were given indomethacin daily; this was administered through the oral route for an additional 10 weeks. At this time, all of the animals were killed and their cheek pouches, the draining cervical lymph nodes, and other organs were removed for examination. The number and size of tumors in each pouch were recorded, and each pouch was weighed. Indomethacin, in the dosage administered, was not found to cause regression of established tumors. The effects of prostaglandins, indomethacin, and other prostaglandin-synthesis inhibitors in tumor tissue are discussed. It is suggested that more knowledge is needed about the role of prostaglandins, and the related products of AA metabolism, in squamous cell cancer before indomethacin is used therapeutically.
D015127:9,10-Dimethyl-1,2-benzanthracene; D000818:Animals; D002610:Cheek; D006224:Cricetinae; D007213:Indomethacin / Q000494:pharmacology* / Q000627:therapeutic use; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D008647:Mesocricetus; D009061:Mouth Mucosa / Q000473:pathology*; D009062:Mouth Neoplasms / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology
D015127:9,10-Dimethyl-1,2-benzanthracene; D007213:Indomethacin